

(701108)

Medical Benefit		Effective Date: 01/01/17	Next Review Date: 11/20
Preauthorization	Yes	Review Dates: 06/07, 07/08, 05/09, 05/10, 03/11, 03/12, 03/13, 03/14, 03/15, 07/15, 07/16, 11/16, 11/17, 11/18, 11/19	

Preauthorization is required.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> • With cervical radicular pain or myelopathy 	Interventions of interest are: <ul style="list-style-type: none"> • Single-level artificial intervertebral disc arthroplasty of the cervical spine 	Comparators of interest are: <ul style="list-style-type: none"> • Anterior cervical discectomy and fusion 	Relevant outcomes include: <ul style="list-style-type: none"> • Symptoms • Morbid events • Functional outcomes • Quality of life • Treatment-related morbidity
Individuals: <ul style="list-style-type: none"> • With cervical radicular pain or myelopathy 	Interventions of interest are: <ul style="list-style-type: none"> • Two-level artificial intervertebral disc arthroplasty of the cervical spine 	Comparators of interest are: <ul style="list-style-type: none"> • Anterior cervical discectomy and fusion 	Relevant outcomes include: <ul style="list-style-type: none"> • Symptoms • Morbid events • Functional outcomes • Quality of life • Treatment-related morbidity

DESCRIPTION

Several prosthetic devices are currently available for artificial intervertebral disc arthroplasty (AIDA) of the cervical spine. AIDA is proposed as an alternative to anterior cervical discectomy and fusion (ACDF) for patients with symptomatic cervical degenerative disc disease.

SUMMARY OF EVIDENCE

For individuals who have cervical radicular pain or myelopathy who receive single-level AIDA of the cervical spine, the evidence includes randomized controlled trials and meta-analyses of randomized controlled trials. Relevant outcomes are symptoms, morbid events, functional outcomes, quality of life, and treatment-related morbidity. At two-year follow-up, trials of all artificial cervical discs met noninferiority criteria. Mid-term outcomes have been reported on five devices (Prestige ST, ProDisc-C, Bryan, Mobi-C, PCM [Porous Coated Motion]). At four to five years, the trial results have been consistent with the continued noninferiority of AIDA for clinical outcomes and lower cumulative reoperation rates. Seven-year follow-up of the Prestige and ProDisc-C pivotal trials continue to show lower secondary surgery rates, although this is not a consistent finding in other reports. Serious adverse events appear to be uncommon. Heterotopic ossification can occur in a substantial proportion

of spinal segments with artificial intervertebral discs but does not appear to lead to a decline in clinical outcomes. The evidence to date shows outcomes that are at least as good as the standard treatment of ACDF. There have been no safety signals with discs approved by the Food and Drug Administration for single-level AIDA. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have cervical radicular pain or myelopathy who receive two-level AIDA of the cervical spine, the evidence includes randomized controlled trials. Relevant outcomes are symptoms, morbid events, functional outcomes, quality of life, and treatment-related morbidity. The Food and Drug Administration approval for the Prestige LP was based on superiority to two-level ACDF in overall success at two years. The increase in overall success rates at two years has been maintained for those patients who have reached the five-year and seven-year follow-ups. At two-year and four-year follow-ups, the first artificial cervical disc approved for two levels (Mobi-C) was found to be superior to ACDF for Neck Disability Index scores, Neck Disability Index success rates, reoperation rates, and overall success composite outcome. At five years, trial results were consistent with the continued superiority of two-level AIDA for clinical outcomes and lower cumulative reoperation rates. Adjacent-segment degeneration with Mobi-C was found in a significantly lower percentage of patients compared with two-level ACDF patients. Based on this evidence, it can be concluded that two-level AIDA with either of these Food and Drug Administration-approved discs is at least as beneficial as the established alternative. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

POLICY

Cervical artificial intervertebral disc implantation may be considered **medically necessary** when ALL of the following criteria are met:

1. The device is approved by the Food and Drug Administration (FDA);
2. The patient is skeletally mature;
3. The patient has intractable cervical radicular pain or myelopathy
 - a. which has failed at least six weeks of conservative nonoperative treatment, including an active pain management program or protocol, under the direction of a physician, with pharmacotherapy that addresses neuropathic pain and other pain sources AND physical therapy; OR
 - b. if the patient has severe or rapidly progressive symptoms of nerve root or spinal cord compression requiring hospitalization or immediate surgical treatment;
4. Degeneration is documented by magnetic resonance imaging, computed tomography, or myelography;
5. Cervical degenerative disc disease is from C3 through C7; and
6. The patient is free from contraindication to cervical artificial intervertebral disc implantation.

Simultaneous cervical artificial intervertebral disc implantation at a second contiguous level may be considered **medically necessary** if the above criteria are met for each disc level, and the device is FDA-approved for two levels (i.e., Mobi-C, Prestige LP).

Subsequent cervical artificial intervertebral disc implantation at an adjacent level may be considered **medically necessary** when all of the following are met:

1. Criteria one to six above are met; AND
2. The device is FDA-approved for two levels; AND

3. The planned subsequent procedure is at a different cervical level than the initial cervical artificial disc replacement; AND
4. Clinical documentation that the initial cervical artificial intervertebral disc implantation is fully healed.

Cervical artificial intervertebral disc implantation is considered **investigational** for all other indications, including the following:

- Disc implantation at more than two levels
- Combined use of an artificial cervical disc and fusion
- Prior surgery at the treated level
- Previous fusion at another cervical level
- Translational instability
- Anatomic deformity (e.g., ankylosing spondylitis)
- Rheumatoid arthritis or other autoimmune disease
- Presence of facet arthritis
- Active infection
- Metabolic bone disease (e.g., osteoporosis, osteopenia, osteomalacia)
- Malignancy

BACKGROUND

CERVICAL DEGENERATIVE DISC DISEASE

Cervical DDD is a manifestation of spinal spondylosis that causes deterioration of the intervertebral discs of the cervical spine. Symptoms of cervical DDD include arm pain, weakness, and paresthesias associated with cervical radiculopathy. Disc herniation, osteophytes, kyphosis, or instability that compress the spinal cord can result in myelopathy, which is manifested by subtle changes in gait or balance, and, in severe cases, leads to weakness in the arms or legs and numbness of the arms or hands. The prevalence of DDD secondary to cervical spondylosis increases with age. An estimated 60% of individuals older than 40 years have radiographic evidence of cervical DDD. By age 65, 95% of men and 70% of women have at least one degenerative change evident at the radiographic examination. It is estimated that approximately five million adults in the United States are disabled to an extent by spine-related disorders, although only a small fraction of those are clear candidates for spinal surgery.

Treatment

Anterior cervical discectomy and fusion (ACDF) has historically been considered the definitive surgical treatment for symptomatic DDD of the cervical spine. The goals of ACDF are to relieve pressure on the spinal nerves (decompression) and to restore spinal column alignment and stability. Resolution of pain and neurologic symptoms may be expected in 80% to 100% of ACDF patients. ACDF involves an anterolateral surgical approach, decompression of the affected spinal level, discectomy, and placement of a PEEK (polyetheretherketone) or titanium interbody cage plus autograft or allograft bone in the prepared intervertebral space to stimulate healing and eventual fusion between the vertebral endplates. A metal anterior cervical plate is attached to the adjoining vertebral bodies to stabilize the fusion site, maintain neck lordosis, and reduce the need for prolonged postoperative brace application that is needed following ACDF without an anterior plate. Although there may be slight differences between autograft and allograft sources in the postoperative rate of union, clinical studies have demonstrated similar rates of postoperative fusion (90%-100%) and satisfactory outcomes using either bone

source. Studies have suggested that altered adjacent-segment kinematics following fusion may lead to adjacent-level DDD and need for secondary surgery.

Artificial intervertebral disc arthroplasty (AIDA) is proposed as an alternative to ACDF for patients with symptomatic cervical DDD. In AIDA, an artificial disc device is secured in the prepared intervertebral space rather than an interbody cage and/or bone. An anterior plate is not used to stabilize the adjacent vertebrae, and postsurgical external orthosis is usually not required. The AIDA was designed to maintain anatomic disc space height, normal segmental lordosis, and physiological motion patterns at the index and adjacent cervical levels. The potential to reduce the risk of adjacent-level DDD above or below a fusion site has been the major reason driving device development and use. Disc arthroplasty and ACDF have very similar surgical indications, primarily unremitting pain due to radiculopathy or myelopathy, weakness in the extremities, or paresthesia. However, the chief complaint in AIDA candidates should be radicular or myelopathic symptoms in the absence of significant spondylosis or spondylolisthesis.

REGULATORY STATUS

In 2007, the Prestige® ST Cervical Disc (Medtronic) was approved by the U.S. Food and Drug Administration (FDA) through the premarket approval (PMA) process as a class III device. The Prestige® ST Cervical Disc is composed of stainless steel and is indicated in skeletally mature patients for reconstruction of the disc from C3 through C7 following single-level discectomy. The device is implanted using an open anterior approach. Intractable radiculopathy and/or myelopathy should be present, with at least one of the following items producing symptomatic nerve root and/or spinal cord compression as documented by patient history (e.g., pain [neck and/or arm pain], functional deficit, and/or neurologic deficit) and radiographic studies (e.g., magnetic resonance imaging, computed tomography, x-rays): herniated disc and/or osteophyte formation. The FDA required Medtronic (the Prestige disc manufacturer) to conduct a seven-year post-approval clinical study of the safety and function of the device and a five-year enhanced surveillance study to more fully characterize adverse events in a broader patient population.

In 2014, the Prestige® LP artificial cervical disc (Medtronic Sofamor Danek) was approved by the FDA through the PMA process. The Prestige® LP differs from the original Prestige cervical disc regarding material and fixation. The LP implant is composed of a proprietary titanium-ceramic composite and has two rails that press-fit into holes created during the surgical procedure. In 2016, the Prestige® LP was approved by the FDA for two adjacent levels. A post-approval study will follow the investigational device exemption (IDE) patients who received the Prestige® LP at two contiguous levels for ten years. Medtronic will also submit to the FDA adverse events, device failures, and complaint analysis for ten years. This includes subsequent surgeries, heterotopic ossification, device malfunction, and other serious device-related complications.

Another disc arthroplasty product, the ProDisc-C® (Synthes Spine), was approved by the FDA through the PMA process in 2007. As with the Prestige® ST Cervical Disc, the FDA approval of ProDisc-C® was made conditional on seven year follow-up of the 209 subjects included in the non-inferiority trial, seven-year follow-up of 99 continued-access subjects, and a five-year enhanced surveillance study to characterize more fully adverse events when the device is used under general conditions of use. Post-approval study reports are to be delivered to the FDA annually.

The Bryan® Cervical Disc (Medtronic Sofamor Danek) consists of two titanium-alloy shells encasing a polyurethane nucleus and has been available outside of the United States since 2002. In 2009, the Bryan® Cervical Disc was approved by the FDA for treatment using an anterior approach of single-level cervical DDD defined as any combination of the following: disc herniation with radiculopathy, spondylotic radiculopathy, disc herniation with myelopathy, or spondylotic myelopathy resulting in impaired function and at least one clinical neurologic sign associated with the cervical level to be treated, and necessitating surgery as demonstrated using computed

tomography, myelography and computed tomography, and/or magnetic resonance imaging results. Patients receiving the Bryan® Cervical Disc should have failed at least six weeks of non-operative treatment before implantation. As a condition for device approval, the FDA required Medtronic Sofamor Danek to extend its follow-up of enrolled subjects to ten years after surgery. The study will involve the investigational and control patients from the pivotal IDE study arm, as well as the patients who received the device as part of the continued-access study arm. Also, Medtronic Sofamor Danek must perform a five-year enhanced surveillance study of the disc to characterize more fully adverse events when the device is used in a broader patient population.

More recently, continued FDA approval requires completion of two post-approval studies. One study provides extended follow-up of the premarket pivotal cohort out to seven years. The second study provides ten-year enhanced surveillance of adverse event data. Continued approval is contingent on submission of annual reports, which include the number of devices sold, heterotopic ossification, device malfunction, device removal, other serious device-related complications, and analysis of all explanted discs.

The following have also received the FDA approval:

- The PCM [porous-coated motion] Cervical Disc® (NuVasive) received the FDA approval in 2012 (P100012). The PCM® is a semi-constrained device consisting of two metal (cobalt-chromium alloy) endplates and a polyethylene insert that fits between the endplates.
- SECURE®-C (Globus Medical) was approved in 2012 (P100003). The SECURE®-C is a three-piece semi-constrained device with two metal (cobalt-chromium molybdenum alloy) endplates and a polyethylene insert.
- The Mobi-C® (LDR Spine) received the FDA approval in 2013. Mobi-C® is three-piece semi-constrained device with metal (cobalt-chromium alloy) endplates and a polyethylene insert. The Mobi-C® is approved for 1- (P110002) or 2-level (P110009) disc replacement.

A number of other devices are in the FDA IDE trials in the United States (see Table 1).

Table 1. Cervical Disc Prostheses Under Investigation in the United States

Prosthesis	Manufacturer	FDA Status
Kineflex/C®	SpinalMotion	FDA IDE trial complete; status unknown
Freedom®	AxioMed	FDA IDE trial recruiting
M6-C	Spinal Kinetics	FDA IDE trial recruiting complete

FDA: U.S. Food and Drug Administration; IDE: investigational device exemption

Updates on the regulatory status of these devices are available online using FDA product code MJO (available at: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>).

RELATED PROTOCOL

Artificial Intervertebral Disc: Lumbar Spine

Services that are the subject of a clinical trial do not meet our Technology Assessment and Medically Necessary Services Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment and Medically Necessary Services Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced

procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disc disease of the cervical spine. TEC Assessments. 2007;Volume 22:Tab 12.
2. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disc disease of the cervical spine. TEC Assessments. 2009;Volume 24:Tab 3.
3. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disease of the cervical spine. TEC Assessments. 2011;Volume 26:Tab 5.
4. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disc disease of the cervical spine. TEC Assessments. 2013;Volume 28:Tab 13.
5. Hu Y, Lv G, Ren S, et al. Mid- to long-term outcomes of cervical disc arthroplasty versus anterior cervical discectomy and fusion for treatment of symptomatic cervical disc disease: a systematic review and meta-analysis of eight prospective randomized controlled trials. *PLoS One*. Feb 2016;11(2):e0149312. PMID 26872258
6. Burkus JK, Traynelis VC, Haid RW, Jr., et al. Clinical and radiographic analysis of an artificial cervical disc: 7-year follow-up from the Prestige prospective randomized controlled clinical trial: Clinical article. *J Neurosurg Spine*. Oct 2014;21(4):516-528. PMID 25036218
7. Sasso RC, Anderson PA, Riew KD, et al. Results of cervical arthroplasty compared with anterior discectomy and fusion: four-year clinical outcomes in a prospective, randomized controlled trial. *J Bone Joint Surg Am*. Sep 21 2011;93(18):1684-1692. PMID 21938372
8. Phillips FM, Geisler FH, Gilder KM, et al. Long-term outcomes of the US FDA IDE prospective, randomized controlled clinical trial comparing PCM cervical disc arthroplasty with anterior cervical discectomy and fusion. *Spine (Phila Pa 1976)*. May 15 2015;40(10):674-683. PMID 25955086
9. Coric D, Kim PK, Clemente JD, et al. Prospective randomized study of cervical arthroplasty and anterior cervical discectomy and fusion with long-term follow-up: results in 74 patients from a single site. *J Neurosurg Spine*. Jan 2013;18(1):36-42. PMID 23140129
10. Davis RJ, Nunley PD, Kim KD, et al. Two-level total disc replacement with Mobi-C cervical artificial disc versus anterior discectomy and fusion: a prospective, randomized, controlled multicenter clinical trial with 4-year follow-up results. *J Neurosurg Spine*. Jan 2015;22(1):15-25. PMID 25380538
11. Hisey MS, Bae HW, Davis RJ, et al. Prospective, randomized comparison of cervical total disk replacement versus anterior cervical fusion: results at 48 months follow-up. *J Spinal Disord Tech*. May 2015;28(4):E237-243. PMID 25310394
12. Janssen ME, Zigler JE, Spivak JM, et al. ProDisc-C Total Disc replacement versus anterior cervical discectomy and fusion for single-level symptomatic cervical disc disease: seven-year follow-up of the prospective randomized U.S. Food and Drug Administration Investigational Device Exemption Study. *J Bone Joint Surg Am*. Nov 4 2015;97(21):1738-1747. PMID 26537161
13. Zhang HX, Shao YD, Chen Y, et al. A prospective, randomised, controlled multicentre study comparing cervical disc replacement with anterior cervical decompression and fusion. *Int Orthop*. Dec 2014;38(12):2533-2541. PMID 25209344

14. Mummaneni PV, Burkus JK, Haid RW, et al. Clinical and radiographic analysis of cervical disc arthroplasty compared with allograft fusion: a randomized controlled clinical trial. *J Neurosurg Spine*. Mar 2007;6(3):198-209. PMID 17355018
15. U.S. Food and Drug Administration (FDA). Report of United States Clinical Study Results (G010188) -- Prestige Cervical Disc System. 2006; https://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4243b1_02.pdf. Accessed March 9, 2018.
16. Burkus JK, Haid RW, Traynelis VC, et al. Long-term clinical and radiographic outcomes of cervical disc replacement with the Prestige disc: results from a prospective randomized controlled clinical trial. *J Neurosurg Spine*. Sep 2010;13(3):308-318. PMID 20809722
17. Gornet MF, Burkus JK, Shaffrey ME, et al. Cervical disc arthroplasty with PRESTIGE LP disc versus anterior cervical discectomy and fusion: a prospective, multicenter investigational device exemption study. *J Neurosurg Spine*. Jul 31 2015;1-16. PMID 26230424
18. Murrey D, Janssen M, Delamarter R, et al. Results of the prospective, randomized, controlled multicenter Food and Drug Administration investigational device exemption study of the ProDisc-C total disc replacement versus anterior discectomy and fusion for the treatment of 1-level symptomatic cervical disc disease. *Spine J*. Apr 2009;9(4):275-286. PMID 18774751
19. Scoliosis Research Society (SRS). Adolescent Idiopathic Scoliosis. n.d.; <http://www.srs.org/professionals/online-education-and-resources/conditions-and-treatments/adolescent-idiopathic-scoliosis>. Accessed March 18, 2019.
20. Delamarter RB, Murrey D, Janssen ME, et al. Results at 24 months from the prospective, randomized, multicenter Investigational Device Exemption trial of ProDisc-C versus anterior cervical discectomy and fusion with 4-year follow-up and continued access patients. *SAS J*. Jan 2010;4(4):122-128. PMID 25802660
21. Zigler JE, Delamarter R, Murrey D, et al. ProDisc-C and anterior cervical discectomy and fusion as surgical treatment for single-level cervical symptomatic degenerative disc disease: five-year results of a Food and Drug Administration study. *Spine (Phila Pa 1976)*. Feb 1 2013;38(3):203-209. PMID 23080427
22. Delamarter RB, Zigler J. Five-year reoperation rates, cervical total disc replacement versus fusion, results of a prospective randomized clinical trial. *Spine (Phila Pa 1976)*. Nov 2 2013;38(9):711-717. PMID 23124255
23. Heller JG, Sasso RC, Papadopoulos SM, et al. Comparison of BRYAN cervical disc arthroplasty with anterior cervical decompression and fusion: clinical and radiographic results of a randomized, controlled, clinical trial. *Spine (Phila Pa 1976)*. Jan 15 2009;34(2):101-107. PMID 19112337
24. Coric D, Nunley PD, Guyer RD, et al. Prospective, randomized, multicenter study of cervical arthroplasty: 269 patients from the Kineflex|C artificial disc investigational device exemption study with a minimum 2-year follow-up: clinical article. *J Neurosurg Spine*. Oct 2011;15(4):348-358. PMID 21699471
25. U.S. Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED): Mobi-C. 2013; https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110002b.pdf. Accessed March 18, 2019.
26. Hisey MS, Bae HW, Davis R, et al. Multi-center, prospective, randomized, controlled investigational device exemption clinical trial comparing Mobi-C Cervical Artificial Disc to anterior discectomy and fusion in the treatment of symptomatic degenerative disc disease in the cervical spine. *Int J Spine Surg*. Feb 2014;8. PMID 25694918
27. Hisey MS, Zigler JE, Jackson R, et al. Prospective, randomized comparison of one-level Mobi-C Cervical Total Disc replacement vs. anterior cervical discectomy and fusion: results at 5-year follow-up. *Int J Spine Surg*. 2016;10:10. PMID 27162712
28. Phillips FM, Lee JY, Geisler FH, et al. A prospective, randomized, controlled clinical investigation comparing PCM cervical disc arthroplasty with anterior cervical discectomy and fusion: 2-year results from the US FDA IDE clinical trial. *Spine (Phila Pa 1976)*. Jul 1 2013;38(15):E907-918. PMID 23591659
29. U.S. Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED): SECURE-C. 2012; https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100003b.pdf. Accessed March 18, 2019.

30. Vaccaro A, Beutler W, Peppelman W, et al. Clinical outcomes with selectively constrained SECURE-C cervical disc arthroplasty: two-year results from a prospective, randomized, controlled, multicenter investigational device exemption study. *Spine (Phila Pa 1976)*. Dec 15 2013;38(26):2227-2239. PMID 24335629
31. U.S. Food and Drug Administration. Summary of Safety and Effectiveness: Prestige LP Cervical Disc. PMA Number P090029/S003. 2016; https://www.accessdata.fda.gov/cdrh_docs/pdf9/p090029s003b.pdf. Accessed March 18, 2019.
32. Davis RJ, Kim KD, Hisey MS, et al. Cervical total disc replacement with the Mobi-C cervical artificial disc compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled multicenter clinical trial. *J Neurosurg Spine*. Nov 2013;19(5):532-545. PMID 24010901
33. Radcliff K, Coric D, Albert T. Five-year clinical results of cervical total disc replacement compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled, multicenter investigational device exemption clinical trial. *J Neurosurg Spine*. Aug 2016;25(2):213-224. PMID 27015130
34. Bae HW, Kim KD, Nunley PD, et al. Comparison of clinical outcomes of 1- and 2-level total disc replacement: four-year results from a prospective, randomized, controlled, multicenter IDE clinical trial. *Spine (Phila Pa 1976)*. Jun 1 2015;40(11):759-766. PMID 25785955
35. Huppert J, Beaurain J, Steib JP, et al. Comparison between single- and multi-level patients: clinical and radiological outcomes 2 years after cervical disc replacement. *Eur Spine J*. Sep 2011;20(9):1417-1426. PMID 21336970
36. Staub LP, Ryser C, Roder C, et al. Total disc arthroplasty versus anterior cervical interbody fusion: use of the Spine Tango registry to supplement the evidence from randomized control trials. *Spine J*. Feb 2016;16(2):136-145. PMID 26674445
37. Chen J, Wang X, Bai W, et al. Prevalence of heterotopic ossification after cervical total disc arthroplasty: a meta-analysis. *Eur Spine J*. Apr 2012;21(4):674-680. PMID 22134486
38. Guyer RD, Shellock J, MacLennan B, et al. Early failure of metal-on-metal artificial disc prostheses associated with lymphocytic reaction: diagnosis and treatment experience in four cases. *Spine (Phila Pa 1976)*. Apr 1 2011;36(7):E492-497. PMID 21252827
39. North American Spine Society. NASS coverage policy recommendations: Cervical artificial disc replacement. 2015; <https://www.spine.org/PolicyPractice/CoverageRecommendations/AboutCoverageRecommendations.aspx>. Accessed March 18, 2019.
40. National Institute for Health and Care Excellence (NICE). Prosthetic intervertebral disc replacement in the cervical spine [IPG341]. 2010; <https://www.nice.org.uk/guidance/ipg341>. Accessed March 9, 2018.
41. Matz PG, Holly LT, Groff MW, et al. Indications for anterior cervical decompression for the treatment of cervical degenerative radiculopathy. *J Neurosurg Spine*. Aug 2009;11(2):174-182. PMID 19769497
42. Mummaneni PV, Kaiser MG, Matz PG, et al. Cervical surgical techniques for the treatment of cervical spondylotic myelopathy. *J Neurosurg Spine*. Aug 2009;11(2):130-141. PMID 19769492
43. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Lumbar Artificial DISC Replacement (LADR) (150.10). 2007; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=313&ncdver=2&CoverageSelection=National&Keyword=disc&KeywordLookup=Title&KeywordSearchType=And&from2=search.asp&bc=gAAAAACAAAAAAA%3d%3d&>. Accessed March 18 2019.